Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

Rosiñol, Laura; Oriol, Albert; Isabel Teruel, Ana; Hernández‐Maraver, Dolores; López‐Jiménez, Javier; de la Rubia, Javier; Granell, Miquel; Besalduch, Joan; Palomera, Luis; González, Yolanda; Asunción Etxebeste, Ma; Diaz‐Mediavilla, Joaquín; Hernández, Miguel‐Teodoro; de Arriba, Felipe; C. Gutiérrez, Norma; Luisa Martín-Ramos, Ma; Teresa Cibeira, M.; Victoria Mateos, Ma; Martínez‐López, Joaquín; Alegre, Adrían; José Lahuerta, Juan; F. San Miguel, Jesús; Bladé, Joan

doi:10.1182/blood-2012-02-408922

Public

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

Published in Blood • Jul 14, 2012

Authors:

Laura Rosiñol

Albert Oriol

Ana Isabel Teruel

Abstract

The Spanish Myeloma Group conducted a trial to compare bortezomib/thalidomide/dexamethasone (VTD) versus thalidomide/dexamethasone (TD) versus vincristine, BCNU, melphalan, cyclophosphamide, prednisone/vincristine, BCNU, doxorubicin, dexamethasone/bortezomib (VBMCP/VBAD/B) in patients aged 65 years ...

Subject

Medicine

Thalidomide

Bortezomib

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!